Anti-biosimilars bill advances in Colo.

02/14/2013 | American City Business Journals · Pharmalot.com

A Colorado House committee passed a bill that would restrict pharmacists' ability to substitute less-expensive biologic drugs for those sold under brand names. Substitution would be allowed only if the FDA has deemed the biosimilar interchangeable with the brand-name drug for the specific indication and if the prescribing doctor allows the substitution.

View Full Article in:

American City Business Journals · Pharmalot.com

Published in Briefs: